MilliporeSigma Collaborates with Angiex on Cancer Drug

Aug 31, 2017
By Pharmaceutical Technology Editors

On Aug. 29, 2017, MilliporeSigma announced a collaboration with Angiex, a biotechnology start-up based in Cambridge, MA, to support the development of TM4SF1, Angiex’s lead oncology antibody drug candidate, to clinical use. The treatment is an antibody-drug conjugate (ADC) therapy for cancer against a vascular target.

The collaboration is the first project to take place at MilliporeSigma’s biodevelopment center in Burlington, MA, set to open in October 2017. Angiex will be given end-to-end process development tools, education programs, and training by the company.

“Companies benefit from our expertise and experience in developing GMP manufacturing processes for early clinical development programs,” said Udit Batra, CEO at MilliporeSigma, in a company press release. “With an end-to-end approach, MilliporeSigma can facilitate and accelerate scaling and technical transfer for companies like Angiex.”

Angiex CEO Dr. Paul Jaminet added: “Through this collaboration, Angiex hopes to accelerate our path to the clinic. We appreciate MilliporeSigma’s expertise in bringing to cancer patients an innovative treatment capable of addressing the most dangerous solid tumors.”

Source: MilliporeSigma

native1_300x100
lorem ipsum